Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense EC-Paclitaxel vs Conventional EC-Docetaxel in HER2-negative Breast Cancer
NCT04576143Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel in breast cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Sep 2020; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04576143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576143.